iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Serum Institute eyes for potential partners to develop Monkeypox Vaccine: Report

27 Jul 2022 , 11:47 AM

World's largest vaccine manufacturer, Serum Institute of India (SII) has initiated discussions with potential partners to develop vaccine against monkeypox, reported The Economic Times.
In a conversation with Economic Times, CEO Adar Poonawalla said that although they are talking with partners to develop a vaccine, there is no urgent need as they are assessing the situation first.
Amid the recent monkeypox cases in India, fresh cases have been suspected in many regions of the country including Bihar, Delhi and Telangana. The news flash rapidly after a 34-year-old man from Delhi with no history of foreign travel tested positive for the monkeypox virus. 
Further, on July 25, a high-level review of the situation was done by the Directorate General of Health Sciences.
On July 23, World Health Organisation (WHO) declared monkeypox a global emergency indicating an extraordinary event that could spill over into more countries and requires a coordinated response globally. 
According to another report by Mint, CEO Poonawalla said if there's a larger breakout of monkeypox cases in India, his company is willing to import a few million doses of a Danish smallpox vaccine. Notably, smallpox vaccines can be used to treat monkeypox.
He also said that Serum Institute is willing to use its own funds to purchase the Danish smallpox vaccine, manufactured by Bavarian Nordic, to vaccinate people against the monkeypox virus.
Speaking to NDTV, he assured that the vaccine will be made as affordable as possible for consumers to treat monkeypox virus, even though no costs have been decided yet.
Reportedly, the SII is also exploring the developments of a new Messenger RNA (mRNA) vaccine for monkeypox virus. Novavax, an American biotechnology company can fulfil the requirements. However, it could take over a year to make a vaccine, he further added.
"We are talking to Novovax. We really need to see the status of this virus, whether there will be a lot of demand or in three to four months it breaks down," Poonawalla told NDTV.

Related Tags

  • Adar Poonawalla
  • CEO Poonawalla
  • covid-19
  • Monkeypox vaccine
  • Monkeypox virus
  • Monkeypox virus news
  • Serum Institute of India
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
29 Mar 2024   |   10:14 AM
Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.